Analyst Price Target is $6.55
▲ +79.45% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is $6.55, with a high forecast of $7.50 and a low forecast of $5.40. The average price target represents a 79.45% upside from the last price of $3.65.
Current Consensus is
The current consensus among 1 polled investment analysts is to hold stock in Knight Therapeutics. This rating has held steady since September 2022, when it changed from a Buy consensus rating.
Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.